ImmunoCellular (IMUC) SPA from FDA 'Significant', Roth Capital Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
- Hertz cuts guidance, announces notes and stock offerings, shares sink
ImmunoCellular Therapeutics (IMUC), FDA Enter Agreement on ICT-107 Phase 3 Special Protocol Assessment
August 13, 2015 6:09 AM EDTImmunoCellular Therapeutics (NYSE: IMUC) has reached agreement with the US Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma. The phase 3 trial is designed as a randomized, double-blind, placebo-controlled study of about 400 HLA-A2 positive subjects, which will be conducted at about 120 sites in the US, Canada and the EU. The primary... More
